Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice

QR Code

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice

Abstract Enteroendocrine L-cell derived peptide hormones, notably glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), have become important targets in the treatment of type 2 diabetes, obesity and intestinal diseases. As gut microbial imbalances and maladaptive host responses have b...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Mette Simone Aae Madsen, Jacob Bak Holm, Albert Pallejà, Pernille Wismann, Katrine Fabricius, Kristoffer Rigbolt, Martin Mikkelsen, Morten Sommer, Jacob Jelsing, Henrik Bjørn Nielsen, Niels Vrang, Henrik H. Hansen
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2019
Sujets:	Medicine R Science Q
Accès en ligne:	https://doaj.org/article/7cc76709e4214ac29b3c51f8c12f05a0
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Targeting GLP-1 receptor trafficking to improve agonist efficacy
par: Ben Jones, et autres
Publié: (2018)

Role and development of GLP-1 receptor agonists in the management of diabetes
par: Chee&nbsp;W Chia, et autres
Publié: (2009)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
par: Neff LM
Publié: (2010)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
par: Lisa M Neff, et autres
Publié: (2010)

Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms
par: Shunsuke Kato, et autres
Publié: (2021)

Activation of the GLP-1 receptor by chloropyrimidine derivatives
par: Shaikha S. AlNeyadi, et autres
Publié: (2021)

GLP-1, SGLT-2, new devices for interventional cardiologists
par: Çetin Erol
Publié: (2021)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
par: Stolar MW, et autres
Publié: (2013)

An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
par: Mustafa Kılıçkap, et autres
Publié: (2021)

Full-length human GLP-1 receptor structure without orthosteric ligands
par: Fan Wu, et autres
Publié: (2020)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
par: Alexander Sergeevich Ametov, et autres
Publié: (2011)

Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
par: Juliette Fremaux, et autres
Publié: (2019)

Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
par: Sergei Pechenov, et autres
Publié: (2021)

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
par: Lee SP, et autres
Publié: (2019)

GLP-1 Induces the Expression of FNDC5 Derivatives That Execute Lipolytic Actions
par: Hui Li, et autres
Publié: (2021)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
par: Chudleigh RA, et autres
Publié: (2020)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
par: Morieri ML, et autres
Publié: (2020)

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo
par: Yanbin Dong, et autres
Publié: (2021)

Systematic Synergy of Glucose and GLP-1 to Stimulate Insulin Secretion Revealed by Quantitative Phosphoproteomics
par: Jia-shu Tang, et autres
Publié: (2017)

GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells
par: Quan Li, et autres
Publié: (2017)

GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: Translational systematic review and meta-analysis protocol of clinical and preclinical studies.
par: Carolina Vaccari, et autres
Publié: (2021)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
par: Qiao Q, et autres
Publié: (2016)

L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease
par: Osama F. Elabi, et autres
Publié: (2021)

GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
par: Shahla Rezaei, et autres
Publié: (2021)

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner
par: Zhongqi Li, et autres
Publié: (2021)

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
par: Kazushi Uneda, et autres
Publié: (2021)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
par: Bastin M, et autres
Publié: (2019)

Activation of ectopic olfactory receptor 544 induces GLP-1 secretion and regulates gut inflammation
par: Chunyan Wu, et autres
Publié: (2021)

Protein-lysine methyltransferases G9a and GLP1 promote responses to DNA damage
par: Vasudeva Ginjala, et autres
Publié: (2017)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
par: Enrique Z. Fisman, et autres
Publié: (2021)

Sennoside A Induces GLP-1 Secretion Through Activation of the ERK1/2 Pathway in L-Cells
par: Ma L, et autres
Publié: (2020)

Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
par: Sikirica MV, et autres
Publié: (2017)

GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor
par: Joseph Fusco, et autres
Publié: (2017)

GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose
par: Yusaku Iwasaki, et autres
Publié: (2018)

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
par: Enrico Longato, et autres
Publié: (2021)

Reduction in GLP-1 secretory capacity may be a novel independent risk factor of coronary artery stenosis
par: Chihiro Nagase, et autres
Publié: (2021)

Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control.
par: Thi-Mai Anh Dao, et autres
Publié: (2011)

Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice
par: Feng Zhang, et autres
Publié: (2021)

Simultaneous Effect of Resveratrol and Probiotics on Insulin Resistance and Glucagon-Like Peptide (GLP-1) Levels in Diabetic Rats
par: A Pegah, et autres
Publié: (2021)

La Controvertida Participación del GLP-1 en los Mecanismos Fisiológicos Desencadenados tras Cirugía Bariátrica
par: Falckenheiner-Soria,Joshua, et autres
Publié: (2019)